GlassScriptPhysician profile
Jonathan W Agins
NPI 1316997687
$2,166.74
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,437 · 2020: $314 · 2021: $232 · 2022: $183.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,111.40 | 2019-2020 | |
| Boston Scientific Corporation | $335.20 | 2019-2022 | |
| Coloplast Corp | $194.10 | 2019-2021 | |
| Axonics, INC. | $107.60 | 2021-2022 | |
| Teleflex LLC | $100.68 | 2021-2022 | |
| Astellas Pharma US INC | $96.93 | 2019 | |
| Abbvie INC. | $79.98 | 2019-2022 | |
| C. R. Bard, INC. & Subsidiaries | $32.20 | 2020 | |
| Endo Pharmaceuticals INC. | $30.82 | 2019-2020 | |
| Mission Pharmacal Company | $20.85 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $18.07 | 2021 | |
| Janssen Biotech, INC. | $15.03 | 2019 | |
| Urogen Pharma, INC. | $12.01 | 2020 | |
| Ferring Pharmaceuticals INC. | $11.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Agins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.